Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
Titel:
Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
Auteur:
Schmieder, Roberta Puehler, Florian Neuhaus, Roland Kissel, Maria Adjei, Alex A Miner, Jeffrey N Mumberg, Dominik Ziegelbauer, Karl Scholz, Arne
Verschenen in:
Neoplasia
Paginering:
Jaargang 15 (2013) nr. 10 pagina's 1161-1171, IN24